DK3328867T3 - Krystallinsk form af fri base af lorlatinib - Google Patents
Krystallinsk form af fri base af lorlatinib Download PDFInfo
- Publication number
- DK3328867T3 DK3328867T3 DK16751665.7T DK16751665T DK3328867T3 DK 3328867 T3 DK3328867 T3 DK 3328867T3 DK 16751665 T DK16751665 T DK 16751665T DK 3328867 T3 DK3328867 T3 DK 3328867T3
- Authority
- DK
- Denmark
- Prior art keywords
- lorlatinib
- free base
- crystalline form
- crystalline
- free
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199418P | 2015-07-31 | 2015-07-31 | |
| US201662352349P | 2016-06-20 | 2016-06-20 | |
| PCT/IB2016/054483 WO2017021823A1 (en) | 2015-07-31 | 2016-07-27 | Crystalline form of lorlatinib free base |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3328867T3 true DK3328867T3 (da) | 2020-11-16 |
Family
ID=56686850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20202336.2T DK3798222T3 (da) | 2015-07-31 | 2016-07-27 | Krystallinsk form af den frie base af lorlatinib |
| DK16751665.7T DK3328867T3 (da) | 2015-07-31 | 2016-07-27 | Krystallinsk form af fri base af lorlatinib |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20202336.2T DK3798222T3 (da) | 2015-07-31 | 2016-07-27 | Krystallinsk form af den frie base af lorlatinib |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10420749B2 (da) |
| EP (2) | EP3328867B9 (da) |
| JP (1) | JP6218253B2 (da) |
| KR (1) | KR102088188B1 (da) |
| CN (3) | CN116063322A (da) |
| AU (1) | AU2016304420B2 (da) |
| BR (1) | BR112017028604A2 (da) |
| CA (1) | CA2937257C (da) |
| CY (1) | CY1123689T1 (da) |
| DK (2) | DK3798222T3 (da) |
| ES (2) | ES2972010T3 (da) |
| FI (1) | FI3798222T3 (da) |
| HK (1) | HK1252845A1 (da) |
| HU (2) | HUE065536T2 (da) |
| MX (2) | MX2018001324A (da) |
| PL (2) | PL3798222T3 (da) |
| PT (2) | PT3328867T (da) |
| RU (1) | RU2018101363A (da) |
| SG (1) | SG10201913200XA (da) |
| SI (2) | SI3328867T1 (da) |
| TW (1) | TWI616449B (da) |
| WO (1) | WO2017021823A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3353341A4 (en) | 2015-09-24 | 2018-10-31 | Cyclenium Pharma Inc. | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same |
| WO2017175091A1 (en) | 2016-04-08 | 2017-10-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| WO2018232506A1 (en) * | 2017-06-22 | 2018-12-27 | Cyclenium Pharma Inc. | MACROCYCLIC COMPOUND LIBRARIES CONTAINING PYRIDINE AND METHODS FOR PREPARING AND USING SAME |
| FI3694863T3 (fi) | 2017-10-10 | 2023-08-18 | Pfizer | Lorlatinibin vapaan emäksen hydraatin kidemuoto |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| EP3784675A1 (en) | 2018-04-23 | 2021-03-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| CN109232607A (zh) * | 2018-09-20 | 2019-01-18 | 沈阳药科大学 | 劳拉替尼的合成方法 |
| WO2020148635A1 (en) * | 2019-01-17 | 2020-07-23 | Pfizer Inc. | Crystalline form of a cdk inhibitor |
| WO2021011345A1 (en) * | 2019-07-18 | 2021-01-21 | Pliva Hrvatska D.O.O | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN110483551B (zh) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | 一种劳拉替尼游离碱的晶体 |
| CN110530998A (zh) * | 2019-09-16 | 2019-12-03 | 山东省药学科学院 | 一种劳拉替尼及含劳拉替尼的制剂中有关物质的检测方法 |
| EP4041396A1 (en) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013525476A (ja) | 2010-05-04 | 2013-06-20 | ファイザー・インク | Ａｌｋ阻害剤としての複素環式誘導体 |
| CN103476770B (zh) * | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| JP5823066B2 (ja) * | 2012-03-06 | 2015-11-25 | ファイザー・インク | 増殖性疾患の治療のための大環状誘導体 |
| EP3013835B1 (en) * | 2013-06-28 | 2017-12-13 | Pfizer Inc | Solid forms of a macrocyclic kinase inhibitor |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| WO2017175091A1 (en) | 2016-04-08 | 2017-10-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| FI3694863T3 (fi) | 2017-10-10 | 2023-08-18 | Pfizer | Lorlatinibin vapaan emäksen hydraatin kidemuoto |
-
2016
- 2016-07-27 ES ES20202336T patent/ES2972010T3/es active Active
- 2016-07-27 EP EP16751665.7A patent/EP3328867B9/en active Active
- 2016-07-27 CN CN202310197825.6A patent/CN116063322A/zh active Pending
- 2016-07-27 RU RU2018101363A patent/RU2018101363A/ru unknown
- 2016-07-27 CN CN202310214099.4A patent/CN116063323A/zh active Pending
- 2016-07-27 US US15/743,894 patent/US10420749B2/en active Active
- 2016-07-27 DK DK20202336.2T patent/DK3798222T3/da active
- 2016-07-27 HU HUE20202336A patent/HUE065536T2/hu unknown
- 2016-07-27 BR BR112017028604A patent/BR112017028604A2/pt not_active Application Discontinuation
- 2016-07-27 MX MX2018001324A patent/MX2018001324A/es unknown
- 2016-07-27 SI SI201631027T patent/SI3328867T1/sl unknown
- 2016-07-27 TW TW105123769A patent/TWI616449B/zh active
- 2016-07-27 DK DK16751665.7T patent/DK3328867T3/da active
- 2016-07-27 HU HUE16751665A patent/HUE052790T2/hu unknown
- 2016-07-27 WO PCT/IB2016/054483 patent/WO2017021823A1/en active Application Filing
- 2016-07-27 EP EP20202336.2A patent/EP3798222B1/en active Active
- 2016-07-27 PL PL20202336.2T patent/PL3798222T3/pl unknown
- 2016-07-27 PT PT167516657T patent/PT3328867T/pt unknown
- 2016-07-27 SI SI201631780T patent/SI3798222T1/sl unknown
- 2016-07-27 JP JP2016146928A patent/JP6218253B2/ja active Active
- 2016-07-27 PT PT202023362T patent/PT3798222T/pt unknown
- 2016-07-27 KR KR1020187002904A patent/KR102088188B1/ko active IP Right Grant
- 2016-07-27 ES ES16751665T patent/ES2842302T3/es active Active
- 2016-07-27 SG SG10201913200XA patent/SG10201913200XA/en unknown
- 2016-07-27 CA CA2937257A patent/CA2937257C/en active Active
- 2016-07-27 CN CN201680042321.5A patent/CN107849060A/zh active Pending
- 2016-07-27 PL PL16751665T patent/PL3328867T3/pl unknown
- 2016-07-27 MX MX2021002220A patent/MX2021002220A/es unknown
- 2016-07-27 AU AU2016304420A patent/AU2016304420B2/en active Active
- 2016-07-27 FI FIEP20202336.2T patent/FI3798222T3/fi active
-
2018
- 2018-09-21 HK HK18112176.1A patent/HK1252845A1/zh unknown
-
2019
- 2019-08-08 US US16/535,747 patent/US11020376B2/en active Active
-
2020
- 2020-12-30 CY CY20201101227T patent/CY1123689T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3328867T3 (da) | Krystallinsk form af fri base af lorlatinib | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3377059T3 (da) | Hæmmere af cxcr2 | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3509581T3 (da) | Formuleringer af (r)-2-amino-3-phenylpropylcarbamat | |
| DK3300500T3 (da) | Triazolagonister af apj-receptoren | |
| DK3554240T3 (da) | Kombinationer af aktive forbindelser | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3180331T3 (da) | Polymorfer af selinexor | |
| DK3157508T3 (da) | Fast oral doseringsform af lipofile forbindelser | |
| DK3259349T3 (da) | Dehydrogenase-katalyseret fremstilling af FDCA | |
| DK3694863T3 (da) | Krystallinsk form af frit basehydrat af lorlatinib | |
| DK3220891T3 (da) | Sublingual formulering af riluzol | |
| DK3365323T3 (da) | Salte af tetracycliner | |
| DK3943070T3 (da) | Langtidsvirkende formuleringer af bedaquilin | |
| DK3390422T3 (da) | Krystalformer af lnt | |
| DK3649781T3 (da) | Forbedring af tvungen grænseopdeling | |
| DK3205683T3 (da) | Sammensætninger og indretninger af poly-4-hydroxybutyrat | |
| DK3511000T3 (da) | Krystallinsk form x2 af grapiprant | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| DK3227325T3 (da) | Sammensætninger med selektive hæmmere af il-6-trans-signalering | |
| DK3529236T3 (da) | Krystalformer af eravacyclin | |
| DK3137449T3 (da) | Fremgangsmåder til fremstilling af substituerede cycloseriner |